Saturday, September 17

All session times are in Eastern Daylight Time (EDT), UTC -4
2:15 pm – 3:15 pm

Novel therapeutics and Molecular Based Tumors Boards for CNS tumors; Role of a Nurse Investigator Committee within Clinical Trial Consortiums (231)

Nurses and advanced practice providers (APPs) have led an effort to engage nurse scientists in collaborative work within clinical trial consortiums. In the spring of 2021 a new nursing and APP committee was created within the Pediatric Neuro-Oncology Consortium (PNOC). Prior to finalizing the structure of this committee, a one-time, de-identified survey was distributed to all members of PNOC. A total of 68 surveys were returned from 20 different institutions spanning across the globe.
2:15 pm – 3:15 pm

Antiracism in Nursing: Where Do We Begin? (232)

In May of 2020, the murder of George Floyd and the resulting unrest that ensued, sparked outrage throughout our community and around the world. Given the proximity of this event to our hospital, a group of 5 BIPOC (Black, Indigenous, and People of Color) nurses came together to share experiences and highlight disparities, which resulted in the formation of an employee resource group, FUSION (Facilitators of Unity & Strengtheners of Inclusivity of Nursing). They identified that the healthcare system had racist biases and behaviors built into the workplace, which negatively impacted health outcomes for BIPOC, pediatric patients and staff. FUSION began to identify pitfalls and opportunities for improvement related to diversity, equity, and inclusion in the pediatric care areas.
2:45 pm – 3:15 pm

Renewed Hope for the Future: Menin Inhibitors for Relapsed/Refractory Leukemia (233)

Prognosis for pediatric patients and adolescents with multiple relapsed/refractory leukemia remains grim. Many have received relapsed protocols, CAR-T therapies, stem cell transplants and yet, the disease returns. In the past, the next discussion in this patient population would lead towards palliation and quality of life, with little hope for cure. Recent advancement in therapy for children with refractory leukemia has introduced the use of menin inhibitor in patients with KMT2A/MLL and NPM1 mutations, providing a number of young patients with another chance of remission and a chance at a cure.
2:15 pm – 3:15 pm

Strategies in Survivorship Care: Addressing Current Long-term Follow-up Surveillance Gaps Through Individualized Survivorship Care Plans And Specialty Survivorship Clinics (234) 

With current 10-year survival rates greater than 80% for pediatric, adolescent, and young adult (AYA) cancer patients there exists and ever-increasing population of pediatric and AYA cancer survivors. Pediatric and AYA survivors who finish cancer-directed treatment are often burdened with significant risks for long-term complications. This includes risks of secondary cancers and accelerated development of usual age-related comorbid conditions such as heart failure, kidney disease and osteopenia. Given these risks, cancer survivors require specialized health care monitoring and surveillance. The Childhood Cancer Survivor Study has identified significant, suboptimal adherence to COG screening guidelines for secondary malignancies (breast, colorectal, and skin) and cardiac disease amongst this high-risk population. Many survivors and their caregivers also report that they feel uninformed yet worried about potential late effects. This current gap emphasizes the importance of individualized survivorship care post cancer treatment, both short and long term.

Speaker:
Stephanie Neerings MSN APRN FNP-BC
CNE Hours
1